Nonalcoholic Steatohepatitis

NASH-linked changes impact metformin pharmacokinetics

(HealthDay)—Nonalcoholic steatohepatitis (NASH)-associated changes in liver function affect kidney transporter expression and metformin pharmacokinetics, according to an experimental study published online May 27 in Diabetes ...

Jun 04, 2015
popularity6 comments 0

Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Air pollutants linked to abnormal fetal growth

Chinese mothers who were exposed to a high level of certain air pollutants during pregnancy had a higher risk of abnormal fetal growth, according to a new Yale School of Public Health (YSPH) study.

Glaucoma study finds brain fights to preserve vision

A team of researchers, led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve ...